Asterias Biotherapeutics, Inc.

AST's Financial Statements and Analysis

Asterias Biotherapeutics, Inc. narrowed III. Quarter net loss per share of $-0.14 compare to net loss per share of $-0.24 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.18 realized in previous quarter.

Asterias Biotherapeutics's Revenue
fell by
% in III. Quarter (Sep 30 2017) year on year,
to $2
million and
advanced by
434.18 % sequentially.

Book value fell by -15.76 % sequentially to $0.64 per share, -18.32% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.31 per share from $ 0.41.

Book value fell by -15.76 % sequentially to $0.64 per share, -18.32% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.31 per share from $ 0.41.